AR090315A1 - Uso de antitrombina en el tratamiento de pre-eclampsia - Google Patents

Uso de antitrombina en el tratamiento de pre-eclampsia

Info

Publication number
AR090315A1
AR090315A1 ARP130100795A ARP130100795A AR090315A1 AR 090315 A1 AR090315 A1 AR 090315A1 AR P130100795 A ARP130100795 A AR P130100795A AR P130100795 A ARP130100795 A AR P130100795A AR 090315 A1 AR090315 A1 AR 090315A1
Authority
AR
Argentina
Prior art keywords
antithrombin
treatment
eclampsy
antitrombin
glycosylation pattern
Prior art date
Application number
ARP130100795A
Other languages
English (en)
Spanish (es)
Original Assignee
Revo Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revo Biolog Inc filed Critical Revo Biolog Inc
Publication of AR090315A1 publication Critical patent/AR090315A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP130100795A 2012-03-12 2013-03-12 Uso de antitrombina en el tratamiento de pre-eclampsia AR090315A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261609534P 2012-03-12 2012-03-12

Publications (1)

Publication Number Publication Date
AR090315A1 true AR090315A1 (es) 2014-11-05

Family

ID=49161701

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100795A AR090315A1 (es) 2012-03-12 2013-03-12 Uso de antitrombina en el tratamiento de pre-eclampsia

Country Status (12)

Country Link
US (1) US20140206617A1 (enExample)
EP (1) EP2825194A4 (enExample)
JP (1) JP2015509984A (enExample)
KR (1) KR20140135219A (enExample)
CN (1) CN104321076A (enExample)
AR (1) AR090315A1 (enExample)
AU (1) AU2013203512B2 (enExample)
CA (1) CA2871159A1 (enExample)
IN (1) IN2014DN08385A (enExample)
MX (1) MX2014010940A (enExample)
TW (1) TW201400499A (enExample)
WO (1) WO2013138271A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011350895B2 (en) 2010-12-30 2015-05-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
CN104884080A (zh) 2012-08-03 2015-09-02 Lfb美国股份有限公司 抗凝血酶在体外膜式氧合中的用途
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
CA2916566A1 (fr) 2013-07-05 2015-01-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Matrice de chromatographie d'affinite
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
WO2021073518A1 (zh) * 2019-10-17 2021-04-22 中国科学院动物研究所 纤溶酶抑制因子的抑制剂用于预防或治疗子痫前期或子痫的用途
CN113406326B (zh) * 2021-06-01 2022-08-26 大连医科大学 一种用于预测子痫前期的生物学标志物及其应用
CN118593717A (zh) * 2024-05-31 2024-09-06 厦门特宝生物工程股份有限公司 一种用于治疗和/或预防子痫前期发生的药物组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20060292213A1 (en) * 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
JP2008532966A (ja) * 2005-03-11 2008-08-21 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 不活性出発物質からの生理活性糖タンパク質の生成
WO2007014244A2 (en) * 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
US7521632B2 (en) 2006-08-31 2009-04-21 Gaton Corporation Door hinge assembly and enclosure employing the same

Also Published As

Publication number Publication date
JP2015509984A (ja) 2015-04-02
WO2013138271A1 (en) 2013-09-19
AU2013203512A1 (en) 2013-09-26
EP2825194A4 (en) 2015-10-21
IN2014DN08385A (enExample) 2015-05-08
EP2825194A1 (en) 2015-01-21
MX2014010940A (es) 2015-04-13
US20140206617A1 (en) 2014-07-24
KR20140135219A (ko) 2014-11-25
CA2871159A1 (en) 2013-09-19
AU2013203512B2 (en) 2016-02-25
CN104321076A (zh) 2015-01-28
TW201400499A (zh) 2014-01-01

Similar Documents

Publication Publication Date Title
CL2016000373A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
BR112015025709A2 (pt) monoterapia com gla para uso em tratamento de câncer
MX2023007137A (es) Nanomateriales que comprenden acetales unidos a ésteres.
MX2015007888A (es) Compuestos antivirales.
DOP2018000026A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
TW201614068A (en) Fucosidase from bacteroides and methods using the same
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112015032833A2 (pt) métodos e aparelhos para criar um efeito visual em um artigo de borracha
EA033286B1 (ru) Способ лечения или отсрочки развития хронической болезни почек
UY34683A (es) Esteviol glucosiltransferasas y genes que las codifican
CR20110163A (es) Uso de ditiina-tetracarboxamidas para combatir hongos fitopatógenos
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
MX2015008241A (es) Metodos para el tratamiento de espasmos gastrointestinales.
BR112015024281A2 (pt) partículas compósitas e processo para fabricação das mesmas
BR112015005653A2 (pt) Método de promover o desenvolvimento de oócitos maduros e de aumentar a polimerização de actina em tecido ovariano, e uso de um agente que perturba a sinalização na trajetória hippo, ou um agente que age a jusante da sinalização hippo perturbada
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
BR112014007150A2 (pt) artigos abrasivos de redução de ruído
BR112018070188A2 (pt) uso de caulim como opacificante
UY33938A (es) Artículo para fumar que incluye dos o más segmentos de filtro
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2014010714A (es) Terapia de combinacion de procaspasa para gliobastoma.
EP4541541A3 (en) Construction panel having improved fixing strength

Legal Events

Date Code Title Description
FB Suspension of granting procedure